ArticleEClinicalMedicine2025
Prevalence of locoregional and distant lymph node metastases in children and adolescents/young adults with soft tissue sarcomas: a Bayesian meta-analysis of proportions.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of both regional and distant lymph node metastases (LNM) in paediatric and adolescent/young adult (AYA) patients with soft tissue sarcomas (STS) significantly impacts clinical outcomes. However, reported rates of LNM vary widely across the literature and are often accompanied by substantial uncertainty. We aimed to quantitatively synthesise global proportions of LNM across different histological subtypes and tumour sites in this population. Methods: In this meta-analysis, we systematically searched MEDLINE, Scopus, and Web of Science from inception until May 1, 2024 (updated on June 1, 2025) for studies published in English that reported LNM rates in patients with STS aged 0-21 years. Eligible study designs included cohort studies, case-control studies, case series, and randomised controlled trials. Patient-level data were not requested from study authors. LNM had to be confirmed clinically, by imaging, or histologically. We excluded reviews, editorials, and case reports with fewer than three patients. We conducted a random-effects Bayesian meta-analysis using a logit transformation to synthesise LNM proportions. The posterior distributions of LNM prevalence were summarised by the posterior mean and 95% credible intervals (CrIs). Study quality was assessed across seven domains: confounding, participant selection, exposure classification, deviations from intended exposures, missing data, outcome measurement, and selective reporting. Findings: Of 3969 records screened, 263 articles were included in the data synthesis. These comprised 147 studies on rhabdomyosarcoma (RMS), 106 on non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), and 10 on mixed RMS/NRSTS cohorts, representing 53,093 patients with STS. The pooled posterior mean proportion of LNM in patients with RMS (n = 41,547) was 0.228 (95% CrI: 0.202-0.255), with the highest rates observed in patients with alveolar RMS (posterior mean proportion: 0.370; 95% CrI: 0.276-0.473). Subgroup analysis by RMS primary site revealed the highest LNM rates in the perianal/perineal region (0.466; 95% CrI: 0.397-0.537), extremity (0.281; 0.210-0.363), and non-parameningeal head/neck region (0.259; 0.167-0.376). Among patients with NRSTS (n = 11,546), the pooled posterior mean proportion of LNM was 0.111 (95% CrI: 0.092-0.133), with desmoplastic small round cell tumour (0.440; 0.335-0.552), clear cell sarcoma (0.212; 0.163-0.275), and malignant rhabdoid tumour (0.199; 0.141-0.273) showing the highest rates. Most analyses had moderate-to-high heterogeneity (95% CrI for tau: 0.7443-1.1139). Interpretation: Our Bayesian meta-analysis synthesises global evidence on the prevalence of LNM in paediatric and AYA patients with STS, highlighting the significant heterogeneity in LNM rates by histological subtype, particularly in NRSTS, and by tumour location, especially in RMS. Future studies should aim to standardise lymph node staging protocols and reporting practices to improve classification accuracy and enhance comparability across studies. Funding: None.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.